Skip to main content
Innovent Biologics, Inc. logo

Innovent Biologics, Inc. — Investor Relations & Filings

Ticker · 1801 ISIN · KYG4818G1010 LEI · 25490058ONL9SCIE1R22 HKEX Manufacturing
Open in API
Filings indexed 445 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1801

About Innovent Biologics, Inc.

http://www.innoventbio.com

Innovent Biologics, Inc. is a biopharmaceutical company established in 2011, dedicated to the development, manufacturing, and commercialization of high-quality innovative medicines. The company specializes in creating biopharmaceutical drugs, including monoclonal antibody candidates, primarily targeting major therapeutic areas such as oncology and cardiovascular diseases. Innovent operates with a mission to deliver high-quality biopharmaceuticals that are affordable. Its research efforts are supported by the Innovent Academy, a platform focused on drug discovery and pioneering innovations.

Recent filings

Filing Released Lang Actions
DISCLOSEABLE TRANSACTIONS - ACQUISITIONS AND SUBSCRIPTION OF INVESTMENT NOTES AND CLARIFICATION IN RELATION TO GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Regulatory Filings Classification · 75% confidence The document is a regulatory announcement filed on HKEX under the Listing Rules, notifying shareholders of “disclosable transactions” (the acquisitions and subscription of investment notes) and providing a clarification on share options. It contains transaction details and compliance disclosures but no standalone financial statements or substantive report content. It does not fit into any of the specialized report categories (e.g., 10-K, IR, ER, CAP) and serves as a general compliance announcement. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-05-22 English
VOLUNTARY ANNOUNCEMENT - NMPA APPROVAL FOR TYVYT (SINTILIMAB INJECTION) IN COMBINATION WITH ELUNATE (FRUQUINTINIB) FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOM
Regulatory Filings Classification · 75% confidence The document is a voluntary corporate announcement by Innovent Biologics regarding regulatory approval of a drug combination (TYVYT® with ELUNATE®) by the NMPA. It contains no financial statements, meeting materials, voting results, or call transcripts. It is not announcing a report publication but is a business/regulatory update. This fits the catch-all Regulatory Filings category (RNS).
2026-05-21 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for an equity issuer listed on the Hong Kong Stock Exchange, specifically under Chapter 19B of the Exchange Listing Rules. It provides comprehensive data on movements in authorised share capital, issued shares, treasury shares, share options, and confirmations related to compliance with listing rules. The document is regulatory in nature, reporting share capital changes and public float sufficiency, but it is not an annual or interim financial report, nor is it an earnings release or management discussion. It is a regulatory filing that updates the exchange and public on share capital movements and compliance confirmations. The document is lengthy (over 12,000 characters) and contains detailed data, but it is not a financial statement or audit report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-07 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2026
Earnings Release Classification · 80% confidence The document is a Hong Kong Exchanges “inside information” announcement providing first quarter 2026 product revenue figures and growth highlights. It is not a full interim report with financial statements but an initial quarterly financial result update (key highlights only). Therefore it aligns with an Earnings Release. Q1 2026
2026-04-30 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 99% confidence The document is the 2025 Environmental, Social and Governance Report issued by Innovent Biologics. It focuses entirely on ESG governance, climate change, resource conservation, social responsibility, stakeholder engagement, and sustainability metrics. The structure follows ESG reporting frameworks (HKEX ESG Reporting Code, GRI, SASB, MSCI) rather than financial performance or regulatory announcements. This aligns directly with the definition of an Environmental & Social Information report.
2026-04-28 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2025 Annual Report' and contains detailed sections typical of a full annual report, including company profile, chairman's statement, financial highlights, management discussion and analysis, report of directors, corporate governance report, independent auditor's report, consolidated financial statements, and notes. The content includes comprehensive financial data for the year ended December 31, 2025, with IFRS and non-IFRS measures, business highlights, strategic outlook, and governance information. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K).
2026-04-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.